Skip to main content
Premium Trial:

Request an Annual Quote

Genaissance Moves into Nutrigenomics with Sciona Licensing Deal

NEW YORK, Nov. 18 (GenomeWeb News) - Genaissance Pharmaceuticals today announced that it has licensed its HAP genotyping technology platform to consumer product biotech firm Sciona.

In exchange for the technology license, Genaissance obtained a 30 percent equity position in the privately traded UK-based company. Genaissance will receive royalties on any products Sciona develops using the HAP technology.

Kevin Rakin, president and CEO of Genaissance, called Sciona "a leader in the emerging market of integrating genetic variation into wellness products." The deal "continues the commercialization of our HAP technology in a variety of new markets," he added.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.